Published in Clin Pharmacol Ther on January 01, 1979
Influence of cimetidine on pharmacokinetics of propranolol. Br Med J (Clin Res Ed) (1981) 2.50
Induction of propranolol metabolism by rifampicin. Br J Clin Pharmacol (1983) 1.13
Effect of heparin administration on plasma binding of benzodiazepines. Br J Clin Pharmacol (1980) 0.91
Unaltered diazepam plasma binding using indwelling heparinized cannulae for sampling. Br J Clin Pharmacol (1980) 0.89
Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction. Br J Clin Pharmacol (1983) 0.89
Heparin administration increases plasma warfarin binding in man. Br J Clin Pharmacol (1979) 0.85
Increased plasma propranolol binding in myocardial infarction. Br J Clin Pharmacol (1980) 0.82
Effect of heparin on serum binding of propranolol in the acute phase of myocardial infarction. Br J Clin Pharmacol (1981) 0.81
Decreased serum protein binding of diazepam and its major metabolite in the neonate during the first postnatal week relate to increased free fatty acid levels. Br J Clin Pharmacol (1984) 0.79
Propranolol disposition in renal failure. Br J Clin Pharmacol (1980) 0.78
Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment. Br J Clin Pharmacol (1980) 0.77
Early kinetics of intravenous propranolol. Br J Clin Pharmacol (1982) 0.77
Unaltered serum propranolol binding by meal-induced variations in fatty acids. Br J Clin Pharmacol (1982) 0.76
Pharmacokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients. Antimicrob Agents Chemother (1994) 0.75
Effects of feeding on the systemic clearance of indocyanine green and propranolol blood concentrations and plasma binding. Br J Clin Pharmacol (1983) 0.75
Reduction of catheter-associated sepsis in parenteral nutrition using heparin. Br Med J (1979) 0.75
Ensembl 2008. Nucleic Acids Res (2007) 20.67
Ensembl 2007. Nucleic Acids Res (2006) 20.10
Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther (1970) 9.54
Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96
A data bank for patient care, curriculum, and research in family practice: 526,196 patient problems. J Fam Pract (1976) 6.06
A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. N Engl J Med (1995) 4.68
Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med (1981) 3.98
Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man. Br Med J (1970) 3.80
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
Results of cataract surgery in young children in east Africa. Br J Ophthalmol (2001) 3.27
Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med (1995) 3.25
Inadequate spinal anaesthesia with 0.5% Marcain Heavy (Batch 1961). Int J Obstet Anesth (2003) 3.23
Disclosure of authors' conflicts of interest: a follow-up. N Engl J Med (2000) 3.16
Longitudinal muscle strength changes in older adults: influence of muscle mass, physical activity, and health. J Gerontol A Biol Sci Med Sci (2001) 3.15
Getting evidence into clinical practice: an organisational behaviour perspective. J Health Serv Res Policy (2000) 3.06
Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat Genet (1999) 3.01
Racial differences in the response to drugs--pointers to genetic differences. N Engl J Med (2001) 2.90
A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol. Arch Intern Med (1972) 2.89
Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol (2001) 2.86
Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther (1979) 2.85
The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med (2001) 2.74
Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res (1998) 2.58
The Ambulatory Sentinel Practice Network: purpose, methods, and policies. J Fam Pract (1984) 2.56
The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther (1973) 2.54
Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med (1978) 2.50
The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology (1972) 2.50
Does prospective monitoring improve cataract surgery outcomes in Africa? Br J Ophthalmol (2002) 2.47
The Dehydrogenation of Alcohols by Streptococci of Group B. J Bacteriol (1942) 2.46
Periodic emission from the gamma-ray binary 1FGL J1018.6-5856. Science (2012) 2.40
The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med (1998) 2.33
Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med (1989) 2.29
Direct myocardial revascularization without extracorporeal circulation. Experience in 700 patients. Chest (1991) 2.28
Content of family practice. Part I. Rank order of diagnoses by frequency. Part II. Diagnoses by disease category and age/sex distribution. J Fam Pract (1976) 2.26
Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther (1973) 2.24
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (1999) 2.24
Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA (1995) 2.18
Operating conditions for ocular surgery under general anaesthesia: an eccentric problem. Eye (Lond) (2006) 2.06
Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog (1998) 2.06
Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer (1989) 1.97
Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation (1979) 1.88
Causes of childhood blindness in east Africa: results in 491 pupils attending 17 schools for the blind in Malawi, Kenya and Uganda. Ophthalmic Epidemiol (1995) 1.87
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos (2000) 1.87
Clinical pharmacokinetics of propranolol. Clin Pharmacokinet (1979) 1.81
Drug therapy: Propranolol. N Engl J Med (1975) 1.79
Clinical pharmacology of propranolol. Circulation (1975) 1.79
The disposition of propranolol. II. Hepatic elimination in the rat. Pharmacology (1972) 1.78
Time to bring down the twin towers in poor Aboriginal hospital care: addressing institutional racism and misunderstandings in communication. Intern Med J (2012) 1.77
Prazosin in normal subjects: plasma levels, blood pressure and heart rate. Br J Clin Pharmacol (1976) 1.75
Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord (1998) 1.75
Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest (1974) 1.74
Lidocaine plasma protein binding. Clin Pharmacol Ther (1980) 1.74
Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells. J Neurochem (1998) 1.72
Radio imaging of the very-high-energy gamma-ray emission region in the central engine of a radio galaxy. Science (2009) 1.66
Potassium-dependent changes in the conformation of the Kv2.1 potassium channel pore. J Gen Physiol (1999) 1.64
Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmacol (1977) 1.64
Cardiovascular effects of prazosin in normotensive and genetically hypertensive rats. Clin Exp Pharmacol Physiol (1975) 1.63
Plasma binding and the affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther (1976) 1.62
Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther (1979) 1.62
Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol (1978) 1.60
Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther (2000) 1.60
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59
Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man. Clin Pharmacol Ther (1973) 1.58
Some limits to evidence-based medicine: a case study from elective orthopaedics. Qual Health Care (1999) 1.57
Primary open-angle glaucoma presentation at a tertiary unit in Africa: intraocular pressure levels and visual status. Ophthalmic Epidemiol (2005) 1.56
Group therapy for adolescents with repeated self harm: randomised controlled trial with economic evaluation. BMJ (2011) 1.55
Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther (1979) 1.55
Nonhemolytic febrile transfusion reactions. Quantitative effects of blood components with emphasis on isoantigenic incompatibility of leukocytes. Vox Sang (1967) 1.54
Adrenergic control of tendon jerk reflexes in man. Br J Pharmacol (1973) 1.54
The imprint of the extragalactic background light in the gamma-ray spectra of blazars. Science (2012) 1.53
Psychosocial and psychosomatic diagnoses in primary care of children. Pediatrics (1980) 1.52
Collaborative research: a sentinel practice system. J Fam Pract (1982) 1.51
Time required for complete recovery from chronic propranolol therapy. N Engl J Med (1973) 1.51
Effect of route of administration on the relationship between -adrenergic blockade and plasma propranolol level. Clin Pharmacol Ther (1972) 1.48
Quality assurance methods and phantoms for magnetic resonance imaging: report of AAPM nuclear magnetic resonance Task Group No. 1. Med Phys (1990) 1.48
Proposed mechanisms of propranolol's antihypertensive effect in essential hypertension. N Engl J Med (1976) 1.47
Editorial: Propranolol withdrawal. N Engl J Med (1975) 1.47
Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. Anesthesiology (1992) 1.46
Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. Drugs (1974) 1.46
The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol. J Pharmacol Exp Ther (1973) 1.43
Increased toxicity and reduced clearance of lidocaine by cimetidine. Ann Intern Med (1982) 1.43
Propranolol withdrawal syndrome - why? Circulation (1978) 1.43
CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. Clin Pharmacol Ther (2000) 1.42
International primary care classifications: the effect of fifteen years of evolution. Fam Pract (1992) 1.42
Identification of alanine dehydrogenase and its role in mixed secretion of ammonium and alanine by pea bacteroids. Mol Microbiol (2000) 1.41
Primary intraocular lens implantation for penetrating lens trauma in Africa. Ophthalmology (1998) 1.40
Dose-related effect of triazolam on postural sway. Clin Pharmacol Ther (1991) 1.39
Increased vascular adrenergic vasoconstriction and decreased vasodilation in blacks. Additive mechanisms leading to enhanced vascular reactivity. Hypertension (2000) 1.38
Individualization of propranolol therapy. Med Clin North Am (1974) 1.37
Plasma concentrations and the time-course of beta blockade due to propranolol. Clin Pharmacol Ther (1975) 1.36
Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med (1980) 1.35
Biological determinants of propranolol disposition in man. Clin Pharmacol Ther (1978) 1.35